ETNB
Price
$14.71
Change
-$0.03 (-0.20%)
Updated
Sep 24, 04:59 PM (EDT)
Capitalization
2.19B
43 days until earnings call
URGN
Price
$18.01
Change
+$0.13 (+0.73%)
Updated
Sep 24, 04:59 PM (EDT)
Capitalization
827.2M
54 days until earnings call
Interact to see
Advertisement

ETNB vs URGN

Header iconETNB vs URGN Comparison
Open Charts ETNB vs URGNBanner chart's image
89bio
Price$14.71
Change-$0.03 (-0.20%)
Volume$37.94K
Capitalization2.19B
UroGen Pharma
Price$18.01
Change+$0.13 (+0.73%)
Volume$76.62K
Capitalization827.2M
ETNB vs URGN Comparison Chart in %
Loading...
ETNB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
URGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ETNB vs. URGN commentary
Sep 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ETNB is a Hold and URGN is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 24, 2025
Stock price -- (ETNB: $14.74 vs. URGN: $17.88)
Brand notoriety: ETNB and URGN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ETNB: 300% vs. URGN: 53%
Market capitalization -- ETNB: $2.19B vs. URGN: $827.2M
ETNB [@Biotechnology] is valued at $2.19B. URGN’s [@Biotechnology] market capitalization is $827.2M. The market cap for tickers in the [@Biotechnology] industry ranges from $97.36B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ETNB’s FA Score shows that 0 FA rating(s) are green whileURGN’s FA Score has 0 green FA rating(s).

  • ETNB’s FA Score: 0 green, 5 red.
  • URGN’s FA Score: 0 green, 5 red.
According to our system of comparison, ETNB is a better buy in the long-term than URGN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ETNB’s TA Score shows that 5 TA indicator(s) are bullish while URGN’s TA Score has 3 bullish TA indicator(s).

  • ETNB’s TA Score: 5 bullish, 5 bearish.
  • URGN’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, ETNB is a better buy in the short-term than URGN.

Price Growth

ETNB (@Biotechnology) experienced а +84.94% price change this week, while URGN (@Biotechnology) price change was -1.05% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was +10.70%, and the average quarterly price growth was +54.52%.

Reported Earning Dates

ETNB is expected to report earnings on Nov 06, 2025.

URGN is expected to report earnings on Nov 17, 2025.

Industries' Descriptions

@Biotechnology (+4.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ETNB($2.19B) has a higher market cap than URGN($827M). ETNB YTD gains are higher at: 88.491 vs. URGN (67.887). URGN has higher annual earnings (EBITDA): -119.79M vs. ETNB (-442.86M). ETNB has more cash in the bank: 561M vs. URGN (196M). ETNB has less debt than URGN: ETNB (37.6M) vs URGN (125M). URGN has higher revenues than ETNB: URGN (91.9M) vs ETNB (0).
ETNBURGNETNB / URGN
Capitalization2.19B827M265%
EBITDA-442.86M-119.79M370%
Gain YTD88.49167.887130%
P/E RatioN/AN/A-
Revenue091.9M-
Total Cash561M196M286%
Total Debt37.6M125M30%
FUNDAMENTALS RATINGS
ETNB vs URGN: Fundamental Ratings
ETNB
URGN
OUTLOOK RATING
1..100
8469
VALUATION
overvalued / fair valued / undervalued
1..100
39
Fair valued
69
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
99100
PRICE GROWTH RATING
1..100
3643
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
7550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ETNB's Valuation (39) in the null industry is in the same range as URGN (69) in the Biotechnology industry. This means that ETNB’s stock grew similarly to URGN’s over the last 12 months.

ETNB's Profit vs Risk Rating (100) in the null industry is in the same range as URGN (100) in the Biotechnology industry. This means that ETNB’s stock grew similarly to URGN’s over the last 12 months.

ETNB's SMR Rating (99) in the null industry is in the same range as URGN (100) in the Biotechnology industry. This means that ETNB’s stock grew similarly to URGN’s over the last 12 months.

ETNB's Price Growth Rating (36) in the null industry is in the same range as URGN (43) in the Biotechnology industry. This means that ETNB’s stock grew similarly to URGN’s over the last 12 months.

ETNB's P/E Growth Rating (100) in the null industry is in the same range as URGN (100) in the Biotechnology industry. This means that ETNB’s stock grew similarly to URGN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ETNBURGN
RSI
ODDS (%)
Bearish Trend 2 days ago
89%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
88%
Momentum
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
87%
MACD
ODDS (%)
Bullish Trend 2 days ago
87%
N/A
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
89%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
88%
Advances
ODDS (%)
Bullish Trend 7 days ago
85%
Bullish Trend 7 days ago
82%
Declines
ODDS (%)
Bearish Trend 9 days ago
86%
Bearish Trend 10 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
83%
Aroon
ODDS (%)
Bearish Trend 6 days ago
88%
Bullish Trend 2 days ago
74%
View a ticker or compare two or three
Interact to see
Advertisement
ETNB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
URGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
OANLX85.36-0.11
-0.13%
Oakmark Select Institutional
AUIAX36.67-0.07
-0.19%
AB Equity Income A
RYBCX64.91-0.29
-0.44%
Rydex Basic Materials C
TSMUX16.96-0.10
-0.59%
Nuveen Quant Small/Mid Cap Eq W
BLYYX37.49-0.32
-0.85%
American Beacon Man Lg Cp Growth Y

ETNB and

Correlation & Price change

A.I.dvisor indicates that over the last year, ETNB has been loosely correlated with AKRO. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if ETNB jumps, then AKRO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ETNB
1D Price
Change %
ETNB100%
-0.87%
AKRO - ETNB
53%
Loosely correlated
+3.08%
IDYA - ETNB
49%
Loosely correlated
+0.04%
NTLA - ETNB
47%
Loosely correlated
-1.04%
BEAM - ETNB
47%
Loosely correlated
-2.79%
ORIC - ETNB
45%
Loosely correlated
-3.14%
More

URGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, URGN has been loosely correlated with AIM. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if URGN jumps, then AIM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To URGN
1D Price
Change %
URGN100%
-0.61%
AIM - URGN
39%
Loosely correlated
-7.03%
ETNB - URGN
38%
Loosely correlated
-0.87%
SCPH - URGN
36%
Loosely correlated
+0.18%
ATXS - URGN
35%
Loosely correlated
-0.80%
PHAT - URGN
35%
Loosely correlated
+1.36%
More